TALPHERA, INC. quarterly report, Q3 FY2021

Filing Summary

Entity note: The supplied filing is AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), not Talphera, Inc. It is a Form 10-Q for the quarter ended September 30, 2021, filed November 15, 2021. Financial amounts below are in U.S. dollars; amounts are in millions unless stated otherwise.

Business context and reporting period

AcelRx develops and commercializes therapies for medically supervised settings. Its principal marketed product was DSUVIA, a sufentanil product for acute pain in certified healthcare facilities. DZUVEO is the European version of DSUVIA; Zalviso is an additional sufentanil product. The company also licensed U.S. rights to ephedrine and phenylephrine pre-filled syringes, subject to FDA approval.

Financial performance and position

• Q3 revenue rose year over year because AcelRx recognized $1.696 million of DZUVEO license revenue under its new Aguettant agreement. Product sales fell 88% in the quarter; the filing attributes the comparison primarily to a significant Department of Defense purchase in Q3 2020. Nine-month revenue fell 40%, while nine-month product sales declined 46%.
• Q3 net loss narrowed by $0.555 million; the nine-month net loss narrowed by $4.279 million. The company remained loss-making and reported an accumulated deficit of $465.667 million.
• At September 30, cash and cash equivalents were $13.271 million and short-term investments were $35.428 million, totaling $48.699 million, versus $42.886 million at December 31, 2020. Current assets were $51.753 million and current liabilities $17.070 million.
• Long-term debt was reported at $15.732 million on the balance sheet, including $8.780 million current and $6.952 million noncurrent. The debt note gives an accrued Oxford loan balance of $15.3 million. The company also reported an $85.981 million liability related to the sale of future royalties.
• Nine-month financing cash inflow was $29.679 million, including $36.360 million of net equity-financing proceeds, partly offset by $6.750 million of debt payments. Common shares outstanding increased to 119.317 million from 98.812 million at year-end 2020.

Material changes, outlook, and risks

• COVID-19-related restrictions on access to hospitals and surgery centers limited sales and promotional activity, delayed formulary decisions, and affected elective procedures. Management expected near-term DSUVIA sales volumes to remain pressured while access restrictions persisted.
• The fully automated DSUVIA packaging line was installed, but testing, acceptance, and FDA approval had been delayed. Management expected FDA approval in 2022 and anticipated the line could significantly reduce cost of goods sold in 2022 and beyond.
• Under the July 2021 DZUVEO agreement, Aguettant received exclusive commercialization rights in specified European territories. AcelRx received a €2.5 million upfront payment (about $2.9 million); it recognized $1.696 million as revenue and recorded $1.237 million as deferred revenue. Additional milestone and sales-based payments are contingent, not guaranteed.
• AcelRx stated existing cash, cash equivalents, and investments were expected to fund operations for at least 12 months from the filing date. It also cautioned that current resources would not fund operations indefinitely and that additional capital would be needed over the long term. No specific revenue or earnings guidance was provided.
• Zalviso’s U.S. NDA resubmission timing remained dependent in part on finalization of FDA opioid approval guidance. The filing highlights unresolved device-error and inadvertent-dispensing questions, potential additional FDA work, and uncertainty about approval and labeling.
• The FDA issued a February 2021 warning letter concerning DSUVIA promotional materials. AcelRx said it had updated materials and expected a close-out letter after specified corrective communications, but could not assure it would receive one.
• A securities class action and three shareholder derivative complaints alleged misleading statements regarding disclosure controls and DSUVIA marketing. The company said it believed the suits were without merit and intended to defend them; it could not estimate a reasonably possible loss.
• After quarter-end, on November 14, 2021, AcelRx agreed to acquire Lowell Therapeutics in a transaction valued at approximately $32.5 million plus net cash and adjustments, including up to $26 million in contingent milestone consideration. Closing was expected in Q4 2021, subject to conditions; the transaction could involve share issuance and dilution.
• Other key risks include dependence on successful DSUVIA commercialization, opioid-related regulatory and reputational scrutiny, manufacturing and supply concentration, reimbursement and formulary access, the need for additional financing, debt covenants, and the obligation to seek a replacement European Zalviso partner.

Important facts for investors to verify

• Confirm the issuer identity: this filing is for AcelRx Pharmaceuticals, Inc., not Talphera, Inc.
• Track DSUVIA sales and facility access, including whether demand improves after COVID-related restrictions and the timing and regulatory approval of the automated packaging line.
• Check cash burn, financing needs, share dilution, Oxford debt terms and payments, and the distinction between the balance-sheet debt carrying amount and the accrued loan balance in the debt note.
• Monitor Aguettant’s DZUVEO launch, actual product supply and sales, and whether contingent milestones or revenue share payments are achieved.
• Follow FDA developments on the DSUVIA warning letter and Zalviso resubmission, and the status, costs, and outcomes of the shareholder litigation.
• Verify whether the Lowell acquisition closed and assess its cash, share consideration, contingent payments, and integration requirements.